Effect of Pycnogenol® on attention-deficit hyperactivity disorder (ADHD): study protocol for a randomised controlled trial

被引:18
|
作者
Verlaet, Annelies A. J. [1 ]
Ceulemans, Berten [2 ]
Verhelst, Helene [3 ]
Van West, Dirk [4 ]
De Bruyne, Tess [1 ]
Pieters, Luc [1 ]
Savelkoul, Huub F. J. [5 ]
Hermans, Nina [1 ]
机构
[1] Univ Antwerp, Dept Pharmaceut Sci, Lab Nutr & Funct Food Sci, Univ Pl 1, B-2610 Antwerp, Belgium
[2] Univ Antwerp Hosp, Neurol, Wilrijkstr 10, B-2650 Edegem, Belgium
[3] Univ Hosp Ghent, Paediat Neurol, Pintelaan 185, B-9000 Ghent, Belgium
[4] Univ Child & Adolescent Psychiat, Hosp Networtk Antwerp, Lindendreef 1, B-2020 Antwerp, Belgium
[5] Wageningen Univ, Cell Biol & Immunol Grp, Elst 1, NL-6709 PG Wageningen, Netherlands
来源
TRIALS | 2017年 / 18卷
关键词
ADHD; ADD; Behaviour; Pycnogenol (R); Antioxidant; Polyphenols; Oxidative stress; Immunity; Catecholamines; PINE BARK EXTRACT; DEFICIT/HYPERACTIVITY DISORDER; OXIDATIVE STRESS; POLYPHENOLIC EXTRACT; CLINICAL-TRIALS; HUMAN HEALTH; CHILDREN; DISEASE; GLUTATHIONE; MICROBIOTA;
D O I
10.1186/s13063-017-1879-6
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Methylphenidate (MPH), the first choice medication for attention-deficit hyperactivity disorder (ADHD), is associated with serious adverse effects like arrhythmia. Evidence on the association of ADHD with immune and oxidant-antioxidant imbalances offers potential for antioxidant and/or immunomodulatory nutritional supplements as ADHD therapy. One small randomised trial in ADHD suggests, despite various limitations, therapeutic benefit from Pycnogenol (R), a herbal, polyphenol-rich extract. Methods: This phase III trial is a 10-week, randomised, double-blind, placebo and active treatment controlled multicentre trial with three parallel treatment arms to compare the effect of Pycnogenol r to MPH and placebo on the behaviour of 144 paediatric ADHD and attention-deficit disorder (ADD) patients. Evaluations of behaviour (measured by the ADHDRating Scale (primary endpoint) and the Social-emotional Questionnaire (SEQ)), immunity (plasma cytokine and antibody levels, white blood cell counts and faecal microbial composition), oxidative stress (erythrocyte glutathione, plasma lipid-soluble vitamins and malondialdehyde and urinary 8-OHdG levels, as well as antioxidant enzyme activity and gene expression), serum zinc and neuropeptide Y level, urinary catecholamines and physical complaints (Physical Complaints Questionnaire) will be performed in week 10 and compared to baseline. Acceptability evaluations will be based on adherence, dropouts and reports of adverse events. Dietary habits will be taken into account. Discussion: This trial takes into account comorbid behavioural and physical symptoms, as well as a broad range of innovative immune and oxidative biomarkers, expected to provide fundamental knowledge on ADHD aetiology and therapy. Research on microbiota in ADHD is novel. Moreover, the active control arm is rather unseen in research on nutritional supplements, but of great importance, as patients and parents are often concerned with the side effects of MPH.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] An integrated theory for Attention-Deficit Hyperactivity Disorder [ADHD]
    Jones, Barry
    Allison, Elizabeth
    [J]. PSYCHOANALYTIC PSYCHOTHERAPY, 2010, 24 (03) : 279 - 295
  • [42] Down Syndrome and Attention-Deficit/Hyperactivity Disorder (ADHD)
    Ekstein, Sivan
    Glick, Benjamin
    Weill, Michal
    Kay, Barrie
    Berger, Itai
    [J]. JOURNAL OF CHILD NEUROLOGY, 2011, 26 (10) : 1290 - 1295
  • [43] Meditation therapies for attention-deficit/hyperactivity disorder (ADHD)
    Krisanaprakornkit, Thawatchai
    Ngamjarus, Chetta
    Witoonchart, Chartree
    Piyavhatkul, Nawanant
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (06):
  • [44] Genetic findings in Attention-Deficit and Hyperactivity Disorder (ADHD)
    Schimmelmann, Benno Graf
    Friedel, Susann
    Christiansen, Hanna
    Dempfle, Astrid
    Hinney, Anke
    Hebebrand, Johannes
    [J]. ZEITSCHRIFT FUR KINDER-UND JUGENDPSYCHIATRIE UND PSYCHOTHERAPIE, 2006, 34 (06): : 425 - +
  • [45] ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) AND THYROID ABNORMALITIES
    SPENCER, T
    BIEDERMAN, J
    WILENS, T
    GUITE, J
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1994, 33 (06): : 919 - 919
  • [46] THE DOPAMINE THEORY OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)
    LEVY, F
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 1991, 25 (02): : 277 - 283
  • [47] Pharmacotherapy of attention-deficit/hyperactivity disorder (ADHD) in adults
    Kordon, Andreas
    Hofecker Fallahpour, Maria
    [J]. ZEITSCHRIFT FUR PSYCHIATRIE PSYCHOLOGIE UND PSYCHOTHERAPIE, 2006, 54 (02): : 99 - 110
  • [48] Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) in Childhood
    Stephen E. Brock
    [J]. The California School Psychologist, 1999, 4 (1): : 18 - 29
  • [49] Antisaccades in children with attention-deficit hyperactivity disorder (ADHD)
    Klein, C
    Brandenbusch, A
    Raschke, A
    [J]. PSYCHOPHYSIOLOGY, 2000, 37 : S58 - S58
  • [50] Attention-deficit/hyperactivity disorder (ADHD) in the course of life
    Trott, Goetz-Erik
    [J]. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2006, 256 (Suppl 1) : 21 - 25